Whilst I wait for Dame Emma and her GSK plc conference call, thoughts on the continued Aston Martin Lagonda comedy and Next plc commonsense
I always analytically like the pharmaceutical sector, even if I am not enough of a sector geek to be a massive expert. It is getting close to two years since I bought GSK plc (GSK) shares for the first time in a couple of decades. It gave a solid Q3 set of numbers earlier today, talking about “2022 Guidance raised…(as it) expect to deliver growth in sales of between 8%-10% CER and growth in 2022 adjusted operating profit of between 15%-17% CER". It is always better to raise numbers than not, but that does not mean that the management, led by the extremely well remunerated Dame Emma, does not still have a bunch of questions to answer.
- By Chris Bailey
- 2022-11-02 12:34:29